Top 5 International Clinical Trial Sites in Pakistan
Introduction
In an era of accelerating global medical research, Pakistan is increasingly emerging as a viable location for international clinical trials. The advantages include a large and diverse patient population, emerging research infrastructure, and regulatory frameworks which are gradually maturing. For sponsors, CROs (Contract Research Organizations) and biotechnology firms looking for new sites, Pakistan offers potential—provided one chooses trusted, experienced units.
Among these, the Clinical Trial Unit – Premium Medical Complex (CTU-PMC) in Rawalpindi stands out for its end-to-end capabilities (patient recruitment, site infrastructure, regulatory compliance) and ability to execute Phase II, III and IV studies. ctu.pmcpk.com
In this article, we explore five of Pakistan’s top international-ready clinical trial sites, outline their strengths, and consider what makes them attractive for global research collaborations.
1. CTU-PMC (Clinical Trial Unit – Premium Medical Complex)
Located in Rawalpindi, CTU-PMC is a DRAP-approved facility that emphasises high-quality, international-compliant clinical trials. ctu.pmcpk.com
Key Strengths:
- Purpose-built infrastructure: informed consent rooms, screening/vitals areas, investigational product (IP) storage and randomization, sample storage, archiving. ctu.pmcpk.com
- Recruitment capabilities and sponsor‐friendly workflows: patient recruitment, retention, data quality.
- Regulatory alignment: adherence to Good Clinical Practice (GCP) and international standards.
- Strategic value: for sponsors seeking South Asian sites with strong operational capacity.
Why international sponsors might choose CTU-PMC:
- Clear processes and infrastructure reduce risk of delays.
- Patient population accessible yet managed in a controlled environment.
- Aligns with global trial demands for data diversity, speed and quality.
2. Ziauddin University Clinical Trials Unit (Karachi)
The CTU at Ziauddin University (ZU) is a DRAP-approved centre dedicated to conducting Phase II, III and IV trials with a strong emphasis on ethics, patient & public involvement (PPIE), and international benchmark alignment. Ziauddin University
Highlights:
- Advanced infrastructure: –20°C and –80°C freezers, ECG tracing, ICU capacity, audio/visual monitoring for trial operations. Ziauddin University
- Unique PPIE model: involving patients and public in research design and review, which is increasingly valued in global trials.
- Positioned to attract international collaborators seeking culturally responsive and ethically robust sites.
For sponsors: This site offers an urban Karachi base, with access to diverse patient demographics and a responsive research team with international awareness.
3. Shifa Clinical Research Center (Shifa International Hospitals, Islamabad)
At Shifa International Hospital’s Clinical Research Centre, the emphasis is on innovation, ethical research, and collaboration with international networks. Shifa International Hospitals Limited
Features:
- Participation in large-scale global trials (e.g., COVID-19 vaccine trials) with thousands of volunteer participants. Shifa International Hospitals Limited
- Research infrastructure combined with tertiary care hospital environment – useful for trials requiring complex patient management and advanced diagnostics.
- Strong academic/research-hospital linkages, making patient follow-up and data integrity management robust.
Value proposition: For sponsors needing sites that can handle complex protocols, adverse event monitoring, and integration of research into high-end clinical care.
4. Dow University of Health Sciences Clinical Trial Site (Karachi – Ojha Campus)
This clinical trial site, part of the Dow University of Health Sciences (DUHS) in Karachi, is DRAP-approved for Phase I-IV trials and is located within a major teaching and tertiary hospital environment. Dow University of Health Sciences
Strengths include:
- Comprehensive facilities: screening rooms, informed consent rooms, drug administration area, sample processing & storage down to -70 °C. Dow University of Health Sciences
- Large patient base across multiple clinical specialties such as infectious diseases, neurology, transplantation and more.
- In a metro city, offering easy access, logistic infrastructure and multi-specialty support.
Why consider this site: It provides a research-trained environment within a high-volume clinical hospital, and is well suited to multi-specialty and complex trial programs.
5. Rawalpindi Medical University Clinical Trial Unit (Public Sector, Rawalpindi)
This public-sector CTU at Rawalpindi Medical University (RMU) is purpose-built for high-quality clinical research in Pakistan’s public health domain, enhancing the country’s research capacity in the public hospital sector. RAWALPINDI MEDICAL UNIVERSITY
Notable features:
- Located in teaching/university hospital environment, leveraging multiple allied hospitals with large bed capacity and a wide patient pool. RAWALPINDI MEDICAL UNIVERSITY
- Fully licensed for Phase III & IV trials, with infrastructure for research pharmacy, labs and regulatory oversight.
- Good for sponsors seeking sites with public-sector linkage, broader access to real-world patient populations and cost-effective operations.
Use-case: Ideal for large enrolment trials, socio-demographic-diverse patient populations, and studies needing general-hospital settings rather than niche specialty centres.
Comparative Overview: What Differentiates These Sites
Below is a summary of key attributes sponsors should consider when selecting an international clinical trial site in Pakistan:
| Site | Infrastructure & Compliance | Patient Population / Recruitment | City & Access | specialty / advantages |
|---|---|---|---|---|
| CTU-PMC | Purpose-built CTU, GCP standards, end-to-end support | Strong recruitment in Rawalpindi region | Rawalpindi | Balanced infrastructure & operational support |
| ZU CTU | Advanced facilities, PPIE model | Urban Karachi, diverse population | Karachi | Research innovation + ethics focus |
| Shifa CRC | Tertiary hospital research centre, global trial experience | Large volunteer base, Islamabad region | Islamabad | High-care environment, globally oriented |
| DUHS Clinical Site | Teaching hospital environment, large specialties | Multi-specialty patient base, Karachi | Karachi | Volume, logistics & hospital setting |
| RMU CTU | Public university hospital linkage, large allied hospitals | Broad population access in Rawalpindi region | Rawalpindi | Cost-effective, public-sector access |
Why Pakistan is Becoming an Attractive Destination for International Trials
- Large and diverse patient populations – Pakistan offers large numbers of treatment-naïve patients, diverse ethnic groups, and a range of therapeutic areas.
- Improving regulatory landscape – The Drug Regulatory Authority of Pakistan (DRAP) maintains a clinical trial registry and has been improving oversight of human-subject trials. dra.gov.pk+1
- Cost-effectiveness – Operational costs, patient recruitment costs and overheads tend to be lower than many Western trial sites, making Pakistan cost-competitive.
- Emerging infrastructure – Several units now match international GCP standards, with trained staff, cooled sample storage, IT systems, monitoring capability and hospital linkages (as seen above).
- Increasing global collaborations – Pakistani sites are increasingly integrated into multi-centre trials, offering global sponsors access to South-Asian data and patient populations.
Key Considerations When Choosing a Pakistani Clinical Trial Site
For sponsors considering Pakistan, the following factors should be assessed:
- Regulatory compliance and approvals: Has the site successfully worked with DRAP and international sponsors?
- Infrastructure and logistics: Does the site have cooled storage, investigational drug handling, monitoring, data management systems, and audit readiness?
- Recruitment capability: What is the patient pool like? Does the site have strong retention, screening, consent processes?
- Ethics and patient protection: How strong is the informed consent process, ethics board oversight, participant follow-up?
- Data quality and monitoring: Are there trained monitors, query resolution capability, digital systems?
- Geography and accessibility: Proximity to airports, logistic hubs, ability to handle visits and monitor.
- Language and cultural factors: The ability of the site team to work with global sponsors, data standards, documentation in English etc.
- Sponsor oversight and transparency: What sponsor feedback is available? Are there references for timely database lock, query resolution, milestones achieved?
Sites like CTU-PMC aim to meet many of these criteria.
How CTU-PMC Fits Into This Landscape
When evaluating Pakistan as a location for an international trial, the CTU-PMC case exemplifies many strengths:
- It offers purpose-built infrastructure, compliance with GCP and regulatory frameworks.
- It has a recruitment-focused model and appears to have established workflows for sponsors.
- Being based at Premium Medical Complex, it combines clinical hospital environment with research-unit design, likely offering good access to patients and logistic support.
- The internal link to their website (https://ctu.pmcpk.com/) allows interested sponsors or researchers to review their services directly.
By including CTU-PMC as one of your options (and internal linking from your blog), you strengthen your blog’s value and direct readers to a practical, actionable site.
Challenges & Mitigation Strategies
While there’s promise, some challenges exist in Pakistan’s clinical trial ecosystem:
- Regulatory delays or variability: The regulatory system is improving, but timelines may vary compared to mature markets. Sponsors should engage early with DRAP and local site regulatory teams.
- Patient retention and follow-up: In some settings patient follow-up may be challenging due to socio-economic factors. Site teams must have strong patient-engagement strategies.
- Data systems and monitoring sophistication: While many sites are improving, some may still lack advanced digital data capture or real-time monitoring. Sponsors should audit site capabilities.
- Site experience with global sponsors: Not all sites have equal track record. Prior successful enrolment, query resolution and database lock history are useful indicators.
- Logistics and supply chain: Investigational product shipping, cold-chain management and monitoring visits need careful planning in emerging markets.
Mitigation: Choose sites with established track record (like the ones listed above), perform site feasibility visits, include contingency plans for retention, ensure detailed monitoring SOPs and schedule early regulatory engagement.
Tips for Sponsors & CROs Working in Pakistan
- Conduct early feasibility assessments focusing on patient population, site staff experience, infrastructure, previous performance.
- Engage local regulatory and ethics committees early to understand timelines and required documentation.
- Ensure patient-information materials are culturally appropriate and consent processes align with global standards.
- Monitor recruitment progress closely; include local community outreach and retention tactics.
- Plan for monitoring visits with travel/logistics buffer and ensure site has remote monitoring capability if needed.
- Utilize local CRO partners for cultural/linguistic adaptation, regulatory navigation and monitoring support.
- Maintain high data-quality standards: on-site monitoring, query resolution workflows, central data management oversight.
- Consider whether the site has experience in the therapeutic area of interest and local disease prevalence aligns with trial needs.
Conclusion
Pakistan is increasingly a credible destination for international clinical trials, provided that sponsors choose the right site partner. The five sites profiled above – including CTU-PMC, Ziauddin University CTU, Shifa Clinical Research Centre, DUHS Clinical Trial Site and RMU CTU – represent some of the leading institutions in the country with the infrastructure, oversight and patient access to support global trials.
If you are assessing Pakistan for your next Phase II, III or IV trial, you would do well to consider these sites, perform robust feasibility assessments, and ensure alignment with global standards.
And for those who seek a balanced and mature option in the Pakistani market, the CTU-PMC offers a compelling blend of infrastructure, recruitment capability and regulatory alignment.
By leveraging these top sites, international sponsors and CROs can tap into Pakistan’s patient populations, accelerate enrolment, diversify their data and expand global footprints in clinical research.
